India’s health ministry said no to modifying the country’s e-cigarette prohibition, ending years of heavy lobbying by Philip Morris International to sell its heat-not-burn tobacco device IQOS in the world’s seventh-largest cigarette market. Officials confirmed that the Prohibition of Electronic Cigarettes Act of 2019 remains in effect, including both vapes and heated tobacco products, putting public health ahead of tobacco companies’ appeals.
Four-Year Policy Push Ends Without Desired Outcome:
Philip Morris kicked off private talks with top Indian officials and a parliamentary health panel from 2021 to 2025, pushing scientific data on IQOS as a less harmful smoke-free alternative. Company letters urged research and exemptions from the ban, framing heat-not-burn tech as a harm reduction tool amid India’s million-plus annual tobacco deaths.
PMI executives even met with state leaders at Davos in January, praising the long-term importance of IQOS, according to images on LinkedIn. CEO Jacek Olczak criticized the restriction in interviews, calling it ridiculous and ignoring data that smokers quit faster when they had options. The ministry responded harshly to Reuters’ inquiries: “The government of India is not considering revoking, amending or relaxing this ban.” It recommitted to evidence-based controls and cessation efforts, highlighting that the law expressly prohibits heat-not-burn devices; no amendments are planned.
Significant Market Opportunity Lost:
India consumes more than 100 billion cigarettes a year, a prize PMI sees for IQOS development as mature markets saturate. Analyst Andrei Andon-Ionita at Jefferies described it as the “next chapter” of big share grabs, but the door slammed shut. PMI sells IQOS in 79 countries and moved 151 billion units last year, but India’s ban prevents it from competing with rivals like as Juul. Despite no smoke-free initiatives, Marlboro gradually increased its traditional cigarette market share in India. The rejection hampers PMI’s global shift to low-risk products, limiting growth in high-volume emerging markets. Shares fell on the news, but annual gains remained at 23 percent due to broader strategy.
The Public Health Argument exceeds the Business Push:
India’s 2019 law cracks down on teenage vaping, prohibiting manufacturing, importation, sales, and even advertisements or trials. Officials regard e-cigarettes as gateway dangers, particularly since tobacco kills 1.3 million people per year, according to the WHO. PMI stated that IQOS warms tobacco without combustion, reducing pollutants compared to cigarettes, and cited FDA approval elsewhere. Despite data dumps and state talks, New Delhi maintained a cautious stance, opposing carveouts. Critics praise the ban for protecting vulnerable users (kids and low-income people) from nicotine traps. Lobby documents reveal PMI’s strategy: research briefs, harm reduction conversations, and legislative nudges are all stonewalled.
Global Implications for Tobacco Wars:
The decision highlights tensions between tobacco companies seeking smoke-free futures and authorities protecting turf. PMI’s 2025 effort failed because facts contradicted policy, repeating restrictions in Thailand and Australia. India keeps a PMI stronghold on sticks, with no alternatives. CEO Olczak criticized global restrictions as smokers suffer without switches, but health advocates focus prevention over swaps. As the PMI looks to 2026 for growth, India’s strategy is to double down on cigarettes here while pivoting elsewhere. The victory for public health highlights a lasting impact of bans in the face of billion-dollar lobbying efforts.
